Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

Lung Cancer

Volumn 83, Issue 1, 2014, Pages 109-111

  Schwab, Richard ^a   Petak, Istvan ^a,b   Kollar, Mihaly ^a   Pinter, Ferenc ^a   Varkondi, Edit ^a   Kohanka, Andrea ^a   Barti Juhasz, Helga ^a   Schönleber, Julia ^c   Brauswetter, Diana ^b   Kopper, Laszlo ^c   Urban, Laszlo ^d  

^a KPS Medical Biotechnology and Healthcare Services Ltd   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d Matrahaza Healthcare Center and University Teaching Hospital   (Hungary)

Author keywords

C MET; Crizotinib; Non small cell lung cancer; Personalized medicine; Pharmacogenomics; Predictive biomarker; Receptor tyrosine kinase; Squamous cell lung cancer; Targeted therapy

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR;

AGED; ARTICLE; AUTOPSY; CANCER CHEMOTHERAPY; CASE REPORT; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOLECULAR DIAGNOSTICS; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

C-MET; CRIZOTINIB; NON-SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREDICTIVE BIOMARKER; RECEPTOR TYROSINE KINASE; SQUAMOUS CELL LUNG CANCER; TARGETED THERAPY;

AGED; CARCINOMA, SQUAMOUS CELL; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; PERICARDITIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RADIOGRAPHY, THORACIC; RADIOTHERAPY; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR BURDEN;

EID: 84891746435     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.10.006     Document Type: Article

References (15)

1. Gandhi L., Jänne P.A. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012, 15(18(14)):3737-3742.
2. Shaw A.T., Solomon B., Kenudson M.M. Crizotinib and testing for ALK. J Natl Compr Canc Netw 2011, 9(12):1335-1341.
3. Ou S.H., Kwak E.L., Siwak-Tapp C., Dy J., Bergethon K., Clark J.W., et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011, 6(May (5)):942-946.
4. Chi A.S., Batchelor T.T., Kwak E.L., Clark J.W., Wang D.L., Wilner K.D., et al. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012, 30(January 20 (3)):e30-e33.
5. Okamoto W., Okamoto I., Arao T., Kuwata K., Hatashita E., Yamaguchi H., et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 2012, 11(July (7)):1557-1564.
6. Lennerz J.K., Kwak E.L., Ackerman A., Michael M., Fox S.B., Bergethon K., et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011, 29(December 20 (36)):4803-4810.
7. Smolen G.A., Sordella R., Muir B., Mohapatra G., Barmettler A., Archibald H., et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006, 103(February 14 (7)):2316-2321.
8. Chen Y.T., Chang J.W., Liu H.P., Yu T.F., Chiu Y.T., Hsieh J.J., et al. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment. Thorac Oncol 2011, 6(December (12)):2027-2035.
9. Beau-Faller M., Ruppert A.M., Voegeli A.C., Neuville A., Meyer N., Guerin E., et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 2008, 3(April (4)):331-339.
10. Go H., Jeon Y.K., Park H.J., Sung S.W., Seo J.W., Chung D.H. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 2010, 5(March (3)):305-313.
11. Onozato R., Kosaka T., Kuwano H., Sekido Y., Yatabe Y., Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009, 4(January (1)):5-11.
12. Boland J.M., Jang J.S., Li J., Lee A.M., Wampfler J.A., Erickson-Johnson M.R., et al. MET and EGFR Mutations Identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol 2013, 8(May (5)):574-581.
13. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(May 18 (5827)):1039-1043.
14. Petak I., Schwab R., Orfi L., Kopper L., Keri G. Integrating molecular diagnostics into anticancer drug discovery. Nat Rev Drug Discov 2010, 9(July (7)):523-535.
15. Bos M., Gardizi M., Schildhaus H.U., Heukamp L.C., Geist T., Kaminsky B., et al. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 2013, 81(July (1)):142-143.